Group 1 - The core viewpoint is that Kanglong Chemical's business has been minimally affected by the recent U.S. tariffs, as their primary focus is on providing R&D services, with a small proportion of their business related to commercial goods exports [2] - The company has not received any feedback from clients or partners indicating that tariff issues have impacted their business collaborations [2] - Kanglong Chemical is closely monitoring macroeconomic uncertainties and related policy developments, while also advising investors to be aware of investment risks in the context of geopolitical factors [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 中華人民共和國，北京 2025年8月7日 （股份代號：3759） 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 董事會會議通告 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年8月21日（星期四）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2025年6月30日止六個月之中期業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 ...

格隆汇8月7日丨康龙化成(03759.HK)宣布，董事会会议将于2025年8月21日（星期四）举行，藉以（其 中包括）审议及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩。 ...

| 603538 | 美诺华 | -5.28 | 13.44 | -7141.76 | | --- | --- | --- | --- | --- | | 000953 | 河化股份 | 1.00 | 21.58 | -6783.63 | | 688222 | 成都先导 | -3.49 | 6.59 | -6676.58 | | 300363 | 博腾股份 | -1.62 | 4.18 | -6054.08 | | 600196 | 复星医药 | -0.98 | 1.29 | -5749.1 1 | | 688185 | 康希诺 | -2.80 | 5.15 | -5649.33 | | 688131 | 皓元医药 | -2.95 | 3.76 | -5426.18 | | 300683 | 海特生物 | -3.97 | 13.76 | -5362.08 | | 688553 | 汇宇制药 | -1.87 | 2.83 | -5128.77 | | 301096 | 百诚医药 | -2.81 | 6.89 | -4796.39 | | 300149 | 睿智医药 | -1.65 | 8.06 | -3859. ...

格隆汇8月7日丨康龙化成(03759.HK)宣布，董事会会议将于2025年8月21日（星期四）举行，藉以（其 中包括）审议及批准公司及其附属公司截至2025年6月30日止六个月的中期业绩。 ...

Pharmaron Beijing Co., Ltd. 康 龍 化 成（ 北 京 ）新 藥 技 術 股 份 有 限 公 司 （於中華人民共和國註冊成立的股份有限公司） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 中華人民共和國，北京 2025年8月7日 於本公告日期，董事會包括執行董事樓柏良博士、樓小強先生及鄭北女士；非執 行董事李家慶先生及萬璇女士；獨立非執行董事李麗華女士、曾坤鴻先生及余堅 先生。 （股份代號：3759） 康龍化成（北京）新藥技術股份有限公司（「本公司」）董事會（「董事會」）謹此宣 佈，董事會會議將於2025年8月21日（星期四）舉行，藉以（其中包括）審議及批准 本公司及其附屬公司截至2025年6月30日止六個月之中期業績。 承董事會命 康龍化成（北京）新藥技術股份有限公司 主席 樓柏良博士 董事會會議通告 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 本月底法定/註冊股本總額： RMB 1,778,195,525 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | R ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | | 301,537,125 | | ...

Core Insights - The report highlights significant changes in the shareholding ratios of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Increased Shareholding Ratios - The companies with the largest increases in shareholding ratios include: - Hang Seng China Enterprises (02828) with an increase of 4.29%, reaching a holding ratio of 19.02% [1][2] - Dongjiang Environmental (00895) with an increase of 2.08%, reaching a holding ratio of 42.98% [1][2] - Meizhong Jiahe (02453) with an increase of 2.02%, reaching a holding ratio of 32.46% [1][2] - Over the last five trading days, the top gainers in shareholding ratios were: - Hang Seng China Enterprises (02828) with an increase of 11.75% [5] - Changfei Optical Fiber (06869) with an increase of 7.15%, reaching a holding ratio of 45.78% [5] - Zhengzhou Bank (06196) with an increase of 3.95%, reaching a holding ratio of 51.58% [5] Group 2: Decreased Shareholding Ratios - The companies with the largest decreases in shareholding ratios include: - Shandong Molong (00568) with a decrease of 3.32%, holding 58.15% [3][4] - Kanglong Chemical (03759) with a decrease of 1.21%, holding 54.05% [3][4] - Green Leaf Pharmaceutical (02186) with a decrease of 1.09%, holding 39.33% [3][4] - Over the last five trading days, the top decliners in shareholding ratios were: - Shandong Xinhua Pharmaceutical (00719) with a decrease of 5.14%, holding 42.62% [6] - Guolian Minsheng (01456) with a decrease of 2.30%, holding 52.59% [6] - Dongfang Electric (01072) with a decrease of 2.06%, holding 40.71% [6] Group 3: Long-term Trends - Over the last 20 trading days, the companies with the largest increases in shareholding ratios included: - Hang Seng China Enterprises (02828) with an increase of 18.02%, holding 19.02% [8] - Changfei Optical Fiber (06869) with an increase of 17.40%, holding 45.78% [8] - Junda Co., Ltd. (02865) with an increase of 14.19%, holding 27.55% [8] - The companies with the largest decreases in shareholding ratios over the last 20 trading days included: - Shijiazhuang Octagon (09676) with a decrease of 13.12%, holding 9.51% [9] - Marco Digital Technology (01942) with a decrease of 9.35%, holding 43.30% [9] - Tigermed (03347) with a decrease of 8.65%, holding 58.37% [9]

Group 1: Small Molecule CDMO Business - The company focuses on technological innovation to build a leading global CDMO platform for innovative drugs, serving major pharmaceutical companies like Novartis [1] - The sales of the company's Noxintin project raw materials have significantly increased, with sales growing from $507 million in 2017 to $7.822 billion in 2024, reflecting a CAGR of 47.83% [1] - In the first half of 2025, sales reached $4.618 billion, representing a year-on-year growth of 22.27% [1] Group 2: Peptide Conjugate CDMO Services - The company has established a TIDES division to expand peptide conjugate drug and small nucleic acid technology platforms, providing comprehensive CDMO services from preclinical research to commercial production [2] - The company is actively expanding its peptide production capacity, with the second phase of peptide capacity construction initiated by the end of 2024, including the expansion of OEB5 level high-activity workshops [2] Group 3: API Business - The company is strategically positioning itself in the market by focusing on specialty APIs in areas such as anti-infectives, central nervous system drugs, non-steroidal anti-inflammatory drugs, and hypoglycemic agents [3] - Sales of anti-infective APIs increased from 292.46 tons in 2021 to 325.32 tons in 2024, with a CAGR of approximately 3.61% [3] - Sales of central nervous system APIs grew from 863.34 tons in 2021 to 1003.08 tons in 2024, with a CAGR of approximately 5.13% [3] - Sales of non-steroidal APIs rose from 298.93 tons in 2021 to 368.45 tons in 2024, with a CAGR of approximately 7.22% [3] - Sales of hypoglycemic APIs increased from 328.26 tons in 2021 to 362.66 tons in 2024, with a CAGR of approximately 3.38% [3] Group 4: Investment Recommendations - The company is projected to achieve net profits attributable to shareholders of 921 million yuan, 1.052 billion yuan, and 1.158 billion yuan from 2025 to 2027, representing year-on-year growth of 52.0%, 14.2%, and 10.0% respectively [4] - Based on the average valuation of comparable A-share listed companies, a PE ratio of 23 times is assigned for 2025, with an expected EPS of 1.04 yuan per share, leading to a target price of 23.92 yuan per share in six months [4]